Variable regions of heavy chain and light chain of antihuman IL-13R alpha 2 monoclonal antibody

A monoclonal antibody and variable region technology, applied in the field of biomedicine, can solve the problems of high dosage and low affinity of humanized antibodies

Inactive Publication Date: 2009-05-27
FOURTH MILITARY MEDICAL UNIVERSITY
View PDF0 Cites 28 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] In the process of constructing humanized antibodies, the humanized antibodies obtained by using technologies such as phage antibody library have low affinity, and the dosage is large

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Variable regions of heavy chain and light chain of antihuman IL-13R alpha 2 monoclonal antibody
  • Variable regions of heavy chain and light chain of antihuman IL-13R alpha 2 monoclonal antibody
  • Variable regions of heavy chain and light chain of antihuman IL-13R alpha 2 monoclonal antibody

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0017] The present invention will be described in detail below.

[0018] The complete nucleotide sequence of the variable region gene, especially the nucleotide sequence of its functional fragments (such as CDR, etc.) and the amino acid sequence of the antibody variable region, are chimeric antibodies, single-chain antibodies or humanized antibody construction Foundation. To this end, the applicant immunized BALB / c mice with recombinant human IL-13Rα2, prepared a group of mouse anti-human IL-13Rα2 monoclonal antibodies, cloned and screened FMMU that can secrete high-affinity human IL-13Rα2 monoclonal antibodies - IL-13Rα2-7 hybridoma cell line, the hybridoma cell line has the ability of stably secreting antibody.

[0019] Clone the monoclonal antibody light chain and heavy chain variable region genes; the monoclonal antibody variable region gene sequences are shown in SEQ ID NO.3 and SEQ ID NO.4; obtain the monoclonal antibody light chain and heavy chain Chain variable regio...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a variable region of heavy and light chains of an anti-human IL-13R alpha 2 single clone antibody. The invention uses recombinant human IL-13R alpha 2 to immunize a BALB / c rat to prepare a group of rate anti-human IL-13R alpha 2 single clone antibody and screen anti-human IL-13R alpha 2 single clone antibody FMMU-IL-13R alpha 2-7 with high affinity. The variable region genes of heavy and light chains of the single clone antibody are cloned to obtain the sequences of genes and amino acid in the variable region of the heavy and light chains of the single clone antibody, and confirm the uniqueness of the gene and protein sequences. The amino acid sequence of the variable region and the gene sequences encoding the variable zones have great potential application value in single chain antibody, chimeric antibody, humanized antibody or vaccine for treating malignancy with human IL-13R alpha 2 as the target.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, relates to a monoclonal antibody, in particular to a heavy chain and light chain variable region of an anti-human IL-13Rα2 monoclonal antibody (FMMU-IL-13Rα2-7), including its amino acid sequence and its nucleotide sequence. Background technique [0002] Malignant tumors are major diseases that endanger human health, and the treatment methods for them are still in the research and exploration stage. Following the traditional surgical treatment, radiotherapy, chemotherapy and immunotherapy, targeted antibody drug therapy represented by the combination of genetic engineering and protein engineering technology is becoming an emerging research field for the treatment of tumors. widespread attention. [0003] Human IL-13Rα2 is a tumor-specific marker highly expressed on the surface of malignant tumor cells such as human glioma, head and neck cancer, ovarian cancer and kidney cancer, and plays an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/18C12N15/13A61K39/395A61P35/00
Inventor 金伯泉陈丽华宋朝君龚玖瑜徐竹蔚杨琨
Owner FOURTH MILITARY MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap